|
| Press Releases |
|
 |
|
| Monday, March 20, 2023 |
|
|
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ) protofibril antibody lecanemab (generic name, U.S. brand name: LEQEMBI) in people living with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). more info >> |
|
| Tuesday, March 14, 2023 |
|
|
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease |
| Eisai Co., Ltd. announced today that the U.S. Veterans' Health Administration (VHA) is providing coverage of LEQEMBI (lecanemab-irmb) to veterans living with early stages of Alzheimer's disease (AD). VHA healthcare professionals meeting the criteria set forth by the VHA can prescribe LEQEMBI to veterans who fit the VHA's criteria and the U.S. Food and Drug Administration's (FDA) current label. more info >> |
|
| Friday, March 10, 2023 |
|
|
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award |
| Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win). more info >> |
|
| Thursday, March 9, 2023 |
|
|
Eisai Certified as a 2023 Health and Productivity Management Outstanding |
| Eisai Co., Ltd. announced today that it has been certified as a Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
| Monday, March 6, 2023 |
|
|
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's supplemental Biologics License Application (sBLA) for LEQEMBITM (lecanemab-irmb) 100 mg/mL injection for intravenous use, supporting the conversion of the accelerated approval of LEQEMBI to a traditional approval. more info >> |
|
| Thursday, March 2, 2023 |
|
|
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan |
| Biogen Japan Ltd. and Eisai Co., Ltd. announced today the termination of the co-promotion agreement that has been in place since January 2018 for Biogen Japan's multiple sclerosis (MS) treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of March 31, 2023. more info >> |
|
| Tuesday, February 28, 2023 |
|
|
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. more info >> |
|
| Tuesday, February 21, 2023 |
|
|
Dissolution of Bracco-Eisai Joint Venture |
| Bracco Imaging S.p.A. and Eisai Co., Ltd. announced today that the joint venture regarding the company Bracco-Eisai Co., Ltd. (Ratio of Shares Held: Bracco 51% Eisai 49%), will be dissolved as of March 31, 2023. more info >> |
|
| Monday, January 30, 2023 |
|
|
Lecanemab Receives Priority Review Status in Japan |
| Eisai Co., Ltd. and Biogen Inc. announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI), an anti-amyloid-beta (Abeta) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Friday, January 27, 2023 |
|
|
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency |
| Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology, for review following a standard timeline. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
AdsDrama Launches Short-Drama Marketing Ecosystem Launch in the Dominican Republic, Paving the Way for Digital Content Innovation
Mar 14, 2026 05:00 HKT/SGT
|
|
|
General MRO Aerospace Achieves CAAC Certification, Expanding Global Maintenance Capabilities
Mar 13, 2026 22:20 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China
Mar 13, 2026 22:00 HKT/SGT
|
|
|
CITIC Resources Deepens Dual-Engine Strategy of 'Investment + Trading', Continues to Promote High-Quality Development
Mar 13, 2026 21:01 HKT/SGT
|
|
|
uSMART HK Expands to 12 Physical Service Centres in One Year, Accelerating "Online x Offline" O2O Community Finance Strategy
Mar 13, 2026 17:34 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
Mar 13, 2026 17:00 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Completes Handover of WAKASHIO MARU Training Ship for National Institute of Technology, Toyama College
Mar 13, 2026 16:01 JST
|
|
|
Mitsubishi Heavy Industries to Introduce 10MW-Class Centrifugal Chiller for Next-Generation AI Data Centers in North America
Mar 13, 2026 14:10 JST
|
|
|
Revenue Triples in Four Years! Qunabox Group Reports RMB290 Million in Net Profit in 2025
Mar 13, 2026 12:27 HKT/SGT
|
|
|
Spritzer Sparkling's 'Serikan Raya, Sparkling-kan Suasana' Festive Fusion Message Promotes Togetherness and Tradition with a Light, Modern Twist 
Mar 13, 2026 12:45 JST
|
|
|
Guoquan Achieves Simultaneous Growth in Scale and Profitability, Core Operating Profit Increases by 48.2% in 2025
Mar 13, 2026 10:01 HKT/SGT
|
|
|
Founders Metals Upgrades Lower Antino to Advanced Target; Hits 65.9 m of 1.16 g/t Gold
Mar 13, 2026 04:29 HKT/SGT
|
|
|
Hitachi to deliver the world's first 550 kV gas-insulated switchgear in which the entire equipment is SF(6)-free to Chubu Electric Power Grid
Mar 12, 2026 19:40 JST
|
|
|
OrbusNeich Achieves Record-breaking Revenue, Sales Volume and Gross Profit in FY2025, Net Profit Rises to US$42 million, Final Dividend Increases by 20% to HK12 Cents per Share
Mar 12, 2026 18:07 HKT/SGT
|
|
|
Honda Announces Losses Associated with Reassessment of Automobile Electrification Strategy; Revision to Forecast for Consolidated Financial Results; and Future Direction
Mar 12, 2026 19:02 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
